Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice

Mucosal Immunology

Volumn 6, Issue 2, 2013, Pages 393-404

  Domingos Pereira, S ^a   Decrausaz, L ^a   Derre L ^a   Bobst, M ^a   Romero, P ^b   Schiller, J T ^c   Jichlinski, P ^a   Nardelli Haefliger, D ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CPG OLIGODEOXYNUCLEOTIDE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 PROTEIN; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN E7; TUMOR PROTEIN; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; FEMALE GENITAL TRACT TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION; TUMOR VOLUME; UPREGULATION; WART VIRUS;

EID: 84874062317     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2012.83     Document Type: Article

References (49)

1. Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J. & Shah, K. V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55, 244-265 (2002).
2. Schiller, J. T., Castellsague, X., Villa, L. L. & Hildesheim, A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26 (Suppl 10), K53 - K61 (2008).
3. Gissmann, L. & Nieto, K. The therapeutic vaccine: is it feasible? Arch. Med. Res. 40, 493-498 (2009).
4. Schwarz, K. et al. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur. J. Immunol. 33, 1465-1470 (2003).
5. Matsushima, H., Yamada, N., Matsue, H. & Shimada, S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J. Immunol. 173, 531-541 (2004).
6. Schaefer, T. M., Fahey, J. V., Wright, J. A. & Wira, C. R. Innate immunity in the human female reproductive tract: antiviral response of uterine epithelial cells to the TLR3 agonist poly(I:C). J. Immunol. 174, 992-1002 (2005).
7. Charo, I. F. & Ransohoff, R. M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621 (2006).
8. Nasu, K. & Narahara, H. Pattern recognition via the Toll-like receptor system in the human female genital tract. Mediators Inflamm. 2010, 976024 (2010).
9. Soboll, G., Schaefer, T. M. & Wira, C. R. Effect of Toll-like receptor (TLR) agonists on TLR and microbicide expression in uterine and vaginal tissues of the mouse. Am. J. Reprod. Immunol. 55, 434-446 (2006).
10. Nurkkala, M., Nordstrom, I., Telemo, E. & Eriksson, K. MHC expression and chemokine production in the murine vagina following intra-vaginal administration of ligands to toll-like receptors 3, 7 and 9. J. Reprod. Immunol. 73, 148-157 (2007).
11. Decrausaz, L. et al. Induction of Human papillomavirus oncogene-specific CD8 T cell effector responses in the genital mucosa of vaccinated mice. Int. J. Cancer 126, 2469-2478 (2010).
12. Decrausaz, L. et al. A novel mucosal orthotopic murine model of Human papillomavrius-associated genital cancers. Int. J. Cancer 128, 2105-2113 (2011).
13. Decrausaz, L. et al. Parenteral but not mucosal immunization is able to induce regression of human papillomavirus associated genital tumors. Int. J. Cancer 129, 762-772 (2011).
14. Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301, 640-643 (2003).
15. Kato, H. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105 (2006).
16. Meylan, E. et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167-1172 (2005).
17. Latz, E., Visintin, A., Espevik, T. & Golenbock, D. T. Mechanisms of TLR9 activation. J. Endotoxin. Res. 10, 406-412 (2004).
18. Bauer, S. et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl Acad. Sci. USA 98, 9237-9242 (2001).
19. Revaz, V., Debonneville, A., Bobst, M. & Nardelli-Haefliger, D. Monitoring of vaccine-specific gamma interferon inductionin in genital mucosa of mice by real-time reverse-transcription-PCR. Clin. Vacc. Immunol. 5, 757-764 (2008).
20. Lindqvist, M. et al. Unraveling molecular signatures of immunostimulatory adjuvants in the female genital tract through systems biology. PLoS One 6, e20448 (2011).
21. Iwasaki, A. & Medzhitow, R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 10, 987-995 (2004).
22. Pesce, I. et al. Intranasal administration of CpG induces a rapid and transient cytokine response followed by dendritic and natural killer cell activation and recruitment in the mouse lung. J. Innate Immun. 2, 144-159 (2010).
23. Antonelli, L. R. et al. Intranasal poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J. Clin. Invest. 120, 1674-1682 (2010).
24. Ashkar, A. A., Bauer, S., Mitchell, W. J., Vieira, J. & Rosenthal, K. L. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J. Virol. 77, 8948-8956 (2003).
25. Haining, W. N. et al. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin. Cancer Res. 14, 5626-5634 (2008).
26. Borden, E. C. et al. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug. Discov. 6, 975-990 (2007).
27. Kumar, H., Koyama, S., Ishii, K. J., Kawai, T. & Akira, S. Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly ICenhanced antibody production and cytotoxic T cell responses. J. Immunol. 180, 683-687 (2008).
28. Bagchi, A. et al. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J. Immunol. 178, 1164-1171 (2007).
29. Herbst-Kralovetz, M. M. & Pyles, R. B. Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection. J. Virol. 80, 9988-9997 (2006).
30. El Kebir, D., Jozsef, L., Pan, W., Wang, L. & Filep, J. G. Bacterial DNA activates endothelial cells and promotes neutrophil adherence through TLR9 signaling. J. Immunol. 182, 4386-4394 (2009).
31. Kelly, K. A., Chan, A. M., Butch, A. & Darville, T. Two different homing pathways involving integrin beta7 and E-selectin significantly influence trafficking of CD4 cells to the genital tract following chlamydia muridarum infection. Am. J. Reprod. Immunol. 61, 438-445 (2009).
32. Koelle, D. M., Gonzalez, J. C. & Johnson, A. S. Homing in on the cellular immune response to HSV-2 in humans. Am. J. Reprod. Immunol. 53, 172-181 (2005).
33. Hawkins, R. A., Rank, R. G. & Kelly, K. A. Expression of mucosal homing receptor alpha4beta7 is associated with enhanced migration to the Chlamydia-infected murine genital mucosa in vivo. Infect. Immun. 68, 5587-5594 (2000).
34. Zarbock, A., Ley, K., McEver, R. P. & Hidalgo, A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood 118, 6743-6751 (2011).
35. Olive, A. J., Gondek, D. C. & Starnbach, M. N. CXCR3 and CCR5 are both required for T cell-mediated protection against C. trachomatis infection in the murine genital mucosa. Mucosal Immunol. 4, 208-216 (2011).
36. Jakob, T., Walker, P. S., Krieg, A. M., Udey, M. C. & Vogel, J. C. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J. Immunol. 161, 3042-3049 (1998).
37. Li, J. et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J. Immunol. 179, 2493-2500 (2007).
38. Heckelsmiller, K. et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J. Immunol. 169, 3892-3899 (2002).
39. Lonsdorf, A. S. et al. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J. Immunol. 171, 3941-3946 (2003).
40. Furumoto, K., Soares, L., Engleman, E. G. & Merad, M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 113, 774-783 (2004).
41. Najar, H. M. & Dutz, J. P. Topical CpG enhances the response of murine malignant melanoma to dacarbazine. J. Invest. Dermatol. 128, 2204-2210 (2008).
42. van den Boorn, J. G. et al. Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One 5, e10626 (2010).
43. Cerkovnik, P., Jezersek Novakovic, B., Stegel, V. & Novakovic, S. Class C CpG oligodeoxynucleotides as a single agent and in combination with radiotherapy efficiently delayed growth of subcutaneous B16F1 tumors. Innate Immunol. 15, 313-321 (2009).
44. Nierkens, S. et al. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS One 4, e8368 (2009).
45. Geary, S. M., Lemke, C. D., Lubaroff, D. M. & Salem, A. K. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN. Cancer Immunol., Immunother.: CII 60, 1309-1317 (2011).
46. Giannini, S. L., Hubert, P., Doyen, J., Boniver, J. & Delvenne, P. Influence of the mucosal epithelium microenvironment on langerhans cells: implications for the development of squanous intraepithelial lesions of the cervix. Int. J. Cancer 97, 654-659 (2002).
47. Van der Burg, S. H. et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc. Natl Acad. Sci. USA 104, 12087-12092 (2007).
48. Daayana, S. et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br. J. Cancer 102, 1129-1136 (2010).
49. Glueck, R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine 20, S42 - S44 (2001).